BeyondSpring (BYSI) Q1 2025 earnings summary

Executive summary

• Achieved net income of $1.2 million for Q1 2025, reversing a $3.3 million net loss in Q1 2024, driven by a $7.0 million gain from the sale of SEED subsidiary shares.

• Plinabulin advanced in clinical development, with positive Phase 3 results in NSCLC and ongoing investigator-initiated studies in multiple cancer indications.

• Plinabulin demonstrated early efficacy in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapy, with durable responses and favorable safety in over 700 patients.

• SEED's RBM39 degrader achieved complete tumor regression in Ewing sarcoma models; IND filing expected mid-2025.

• SEED divestiture plan underway, with first closing completed and further tranches expected by end of 2026; BeyondSpring retains a 40% equity interest.

Financial highlights

• Q1 2025 consolidated net income was $1.2 million, compared to a net loss of $3.3 million in Q1 2024.

• Net income attributable to BeyondSpring was $4.5 million, reflecting a $7.0 million gain on sale of subsidiary interests.

• Operating expenses increased 27% year-over-year to $2.6 million, with R&D up 21% and G&A up 30%.

• Cash and cash equivalents rose to $6.5 million as of March 31, 2025, from $2.9 million at year-end 2024.

• No revenue from product sales; $0.5 million collaboration revenue from SEED's agreement with Eli Lilly recognized in discontinued operations.

Outlook and guidance

• Expects continued significant expenses and operating losses as clinical development of Plinabulin and other programs progresses.

• Anticipates need for substantial additional funding to support operations and advance product candidates.

• IND submission for RBM39 degrader in Ewing sarcoma on track for mid-2025; additional indications under exploration.

• Plinabulin combinations to be further evaluated in patients resistant to immunotherapies.

• Current financial resources expected to cover operational expenses and capital expenditures for the next 12 months.